II. Indications

III. Contraindications

  1. Recent major bleeding (last 30 days)
  2. Hemodialysis
  3. Bleeding Diathesis
  4. Severe Hypertension (systolic Blood Pressure >200/110 mmHg)
  5. Prior Hemorrhagic Stroke

IV. Mechanism

  1. Inhibits Platelet aggregation via Glycoprotein IIb/IIIa receptors on Platelet plasma membranes
  2. Inhibits Fibrinogen binding to Platelets

V. Dosing

  1. General
    1. Typically administered with Heparin and Aspirin
  2. Acute Coronary Syndrome
    1. Load: 180 mcg/kg IV bolus
    2. Infuse: 2 mcg/kg/min IV for up to 72 hours
  3. Percutaneous Coronary Intervention (PCI)
    1. Bolus 180 mcg/kg IV immediately before procedure and again 10 minutes after the first dose
    2. Infuse: 2 mcg/kg/min IV for 18 to 24 hours after procedure (at least 12 hours)
  4. Renal Impairment (GFR<50 ml/min)
    1. Decrease infusion rate to 1 mcg/kg/min
  5. Obesity (weight >121 kg)
    1. Maximum bolus dose: 22.6 mg
    2. Maximum infusion rate 15 mg/hour (7.5 mg/hour if GFR<50 ml/min)

VI. Adverse Effects

  1. Major Bleeding
  2. Thrombocytopenia
    1. Discontinue if Platelet Count drops to <100,000 Platelets/mm3

VII. Safety

  1. Pregnancy Category B
  2. Unknown safety in Lactation

IX. References

  1. Bansal (2023) Eptifibatide, Treasure Island, StatPearls
    1. https://www.ncbi.nlm.nih.gov/books/NBK541066/
  2. Hamilton (2020) Tarascon Pocket Pharmacopoeia

Images: Related links to external sites (from Bing)

Related Studies

Ontology: eptifibatide (C0253563)

Definition (NCI) A cyclical heptapeptide with anticoagulant activity. Eptifibatide selectively and reversibly binds to and blocks the platelet glycoprotein IIb/IIIa receptor. This prevents the binding of fibrinogen, von Willebrand factor, and other adhesive ligands and leads to an inhibition of platelet aggregation and prevents thrombus development.
Concepts Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116)
MSH C086648
SnomedCT 116065005, 386998009
LNC LP171395-9
English L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic(1-6)-disulfide, eptifibatide, eptifibatide (medication), eptifibatide [Chemical/Ingredient], Eptifibatide (product), Eptifibatide (substance), Eptifibatide, epifibatide, epifibratide, EPTIFIBATIDE
Japanese エプチフィバチド
Spanish eptifibatida (producto), eptifibatida (sustancia), eptifibatida

Ontology: Integrilin (C0950902)

Concepts Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116)
MSH C086648
English Integrilin, eptifibatide (Integrilin), Integrelin, Pfizer brand of eptifibatide, GlaxoSmithKline UK brand of eptifibatide, integrelin, integrilin, Cor brand of eptifibatide, Essex brand of eptifibatide, Key brand of eptifibatide